Calvin Chen

Biography

Dr. Calvin Chen has been instrumental in establishing the pipeline and strategy of TWi Biotechnology. Dr. Calvin Chen brings over 20 years of experience in biotech venture investment, business development, and running startup biotech companies. Dr. Chen joined Anchen Inc. in 2009, where he led the Anchen Pharmaceuticals Taiwan spin-off and the formation of TWi Pharmaceuticals, Inc. Dr. Chen served as the president of TWi Pharmaceuticals during 2012 to 2015. Under leadership, TWi Pharmaceuticals successfully became a publicly listed company in 2013, raisingover US$110M via the IPO. In addition, Dr. Chen has successfully developed and managed business partnerships with Teva, Par (now Endo) and several domestic pharmaceuticals/biotech companies for TWi Pharmaceuticals. Prior to joining TWi, Dr. Chen had a long career as a venture capitalist first with ChenXin Venture Group, the first venture investment firm in Taiwan specialized in healthcare sectors, and then with YFY Biotech Management Company, one of the largest healthcare specialized venture capitals in Taiwan. Dr. Chen’s portfolio companies included Optimer Pharmaceuticals Inc. (NASDAQ: OPTR), Taigen Pharmaceuticals Holding Ltd. (4157 TT), PharmaEngine Inc. (4162 TT), Bionime Co. (4737 TT), Taiwan Liposome Company (4152 TT), TaiMed Biologics Co. (4147 TT), Apex International Co. (Acquired by Parexel, NASDAQ: PRXL), Level Biotechnology Co. (3118 TT), OBI Pharma Inc. (4147 TT), and Mycenax Biotech Inc. (4726 TT). Dr. Chen holds a Ph.D. degree in biotechnology from University of Illinois at Urbana-Champaign in the US, and is a graduate of National Chung-Hsing University in Taiwan.

Research Interest

Toxicology